OliX Pharmaceuticals, Inc.
Clinical-stage company developing RNAi therapeutics for dermal and ophthalmic diseases.
226950 | KO
Overview
Corporate Details
- ISIN(s):
- KR7226950004
- LEI:
- Country:
- South Korea
- Address:
- 경기도 성남시 수정구 고등동 608-3 -, 성남시
- Website:
- https://olixpharma.com
- Sector:
- Manufacturing
Description
OliX Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in the development of therapeutics based on RNA interference (RNAi) technology. The company leverages its proprietary asymmetric siRNA (asiRNA) platform to create treatments that selectively silence disease-causing genes. Its research and development efforts are focused on building a robust pipeline of drug candidates targeting a variety of illnesses with high unmet medical needs. The pipeline has a particular emphasis on ophthalmic and dermal disorders, with key programs addressing conditions such as hypertrophic scars, age-related macular degeneration (AMD), and other fibrotic and ocular diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-11-27 00:00 |
증권발행결과(자율공시)(제3자배정 유상증자)
|
Korean | 5.9 KB | ||
| 2020-11-27 00:00 |
증권발행결과(자율공시)(제1회차 CB)
|
Korean | 5.9 KB | ||
| 2020-11-19 00:00 |
주요사항보고서(유무상증자결정)
|
Korean | 30.2 KB | ||
| 2020-11-19 00:00 |
주권매매거래정지(무상증자)
|
Korean | 4.7 KB | ||
| 2020-11-19 00:00 |
주요사항보고서(전환사채권발행결정)
|
Korean | 42.9 KB | ||
| 2020-11-18 00:00 |
분기보고서 (2020.09)
|
Korean | 1.2 MB | ||
| 2020-11-11 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 105.8 KB | ||
| 2020-10-29 00:00 |
투자판단관련주요경영사항(흉터 재건술 이후 재발 억제 보조요법으로서 OLX10010의 유효성 평가를 위한 무작위배정, 이중 맹검, 개체 내 비교…
|
Korean | 12.7 KB | ||
| 2020-10-07 00:00 |
[기재정정]투자판단관련주요경영사항(건성 및 습성 황반변성 치료제 OLX301A 기술이전 계약 체결)
|
Korean | 21.8 KB | ||
| 2020-10-07 00:00 |
단일판매ㆍ공급계약체결
|
Korean | 11.1 KB | ||
| 2020-10-07 00:00 |
투자판단관련주요경영사항(습성황반변성 및 망막하섬유하증 치료제 OLX301D 기술이전 계약 체결)
|
Korean | 12.2 KB | ||
| 2020-10-05 00:00 |
기업설명회(IR)개최
|
Korean | 7.4 KB | ||
| 2020-09-25 00:00 |
투자판단관련주요경영사항(흉터 재건술 이후 재발 억제 보조요법으로서 OLX10010의 유효성 평가를 위한 무작위배정, 이중 맹검, 개체 내 비교…
|
Korean | 12.0 KB | ||
| 2020-09-18 00:00 |
주식매수선택권부여에관한신고
|
Korean | 13.8 KB | ||
| 2020-09-04 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 114.7 KB |
Automate Your Workflow. Get a real-time feed of all OliX Pharmaceuticals, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for OliX Pharmaceuticals, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for OliX Pharmaceuticals, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
